S Gastrointestinal And Liver Disease 12th Edition Jun 2026

This new edition is now available in several formats, ensuring it fits into modern clinical or academic routines:

The print text is accompanied by robust online access, featuring searchable text, updates on emerging clinical trials, and a library of procedural videos demonstrating advanced endoscopic techniques. 4. Clinical Utility: Who Benefits Most?

The minimally invasive revolution continues. This edition features detailed, step-by-step chapters on:

The 12th edition transitions seamlessly into the digital era through the Expert Consult platform, offering more than just static text. s gastrointestinal and liver disease 12th edition

: Provides the deep pathophysiological foundation required to pass rigorous subspecialty board examinations.

: Fully integrates the new nomenclature for Metabolic Dysfunction-Associated Steatotic Liver Disease ( MASLD ), replacing the historical term NAFLD.

: Outlines the clinical deployment of AI in endoscopy to improve detection rates for GI cancers and precancerous polyps. This new edition is now available in several

The 12th edition proudly welcomes a new senior editorial team, representing a new generation of leaders in the field:

Neoplasia, mucosal immunology, enteric microbiota, and gut sensory transduction.

Whether you are a seasoned clinician or a student just beginning your journey, the 12th edition of this landmark text provides the authoritative, up-to-date, and practical guidance you need in today's fast-evolving medical landscape. The minimally invasive revolution continues

The 12th Edition is a two-volume set available in both hardcover and digital formats. : ~20,750 INR Elsevier Shop : Includes an eBook version with purchase DNA Mart : ~20,999 INR

MASLD, viral hepatitis (B & C), portal hypertension, cirrhosis management, and transplant updates.

In an era of point-of-care digital resources, the question arises: Why invest in a massive textbook? The answer lies in . UpToDate or DynaMed provide excellent, discrete answers. But Sleisenger and Fordtran’s 12th Edition provides the conceptual framework—the why behind the what . It connects pathophysiology to clinical practice, explains the evidence for contradictory guidelines, and offers historical context that informs current decision-making.

From the rebranding of NAFLD to MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) to the latest curative protocols for Hepatitis C and management of cirrhosis complications, the liver sections are more robust than ever.